PURPOSE: To find a prognostic factor for patients with oropharyngeal cancer (OPC) who were followed for long term after definitive radiotherapy. METHODS: OPC patients that had been treated with radiotherapy at our institution were reviewed. Sex, age, performance status (PS), subsite, disease stage, T-stage, N-stage, RT dose, concurrent chemotherapy, the duration of RT, hemoglobin concentration before any treatment, and a double cancer were assessed for their impact on overall survival (OS) and locoregional control (LRC). RESULTS: Among a total of 141 patients enrolled into this retrospective study, the disease of most patients (81%) was stage III or IV. The median follow-up time of the surviving patients was 56 months (range 5-175 months). Radiotherapy was administered in conventional fractionation, and the median RT dose was 66 Gy. Most patients (90%) received systemic chemotherapy. The 5-year estimates of progression-free survival, LRC, and OS were 66.0, 72.7, and 65.1%, respectively. In the univariate analysis, LRC and OS in the lateral wall at the primary site, T-stage <or=3, and PS <or=1 groups were significantly superior to those in the other groups, and OS in age <or=60 or the hemoglobin level >13.0 g/dL groups were also significantly superior to those in the other groups. In the multivariate analysis, age and T-stage remained significant factors for OS. CONCLUSIONS: Primary radiotherapy was recommended for OPC patients with the lateral wall at the primary site because of good LRC. The treatment method to the older population and T4 tumor is future tasks.
PURPOSE: To find a prognostic factor for patients with oropharyngeal cancer (OPC) who were followed for long term after definitive radiotherapy. METHODS: OPC patients that had been treated with radiotherapy at our institution were reviewed. Sex, age, performance status (PS), subsite, disease stage, T-stage, N-stage, RT dose, concurrent chemotherapy, the duration of RT, hemoglobin concentration before any treatment, and a double cancer were assessed for their impact on overall survival (OS) and locoregional control (LRC). RESULTS: Among a total of 141 patients enrolled into this retrospective study, the disease of most patients (81%) was stage III or IV. The median follow-up time of the surviving patients was 56 months (range 5-175 months). Radiotherapy was administered in conventional fractionation, and the median RT dose was 66 Gy. Most patients (90%) received systemic chemotherapy. The 5-year estimates of progression-free survival, LRC, and OS were 66.0, 72.7, and 65.1%, respectively. In the univariate analysis, LRC and OS in the lateral wall at the primary site, T-stage <or=3, and PS <or=1 groups were significantly superior to those in the other groups, and OS in age <or=60 or the hemoglobin level >13.0 g/dL groups were also significantly superior to those in the other groups. In the multivariate analysis, age and T-stage remained significant factors for OS. CONCLUSIONS: Primary radiotherapy was recommended for OPC patients with the lateral wall at the primary site because of good LRC. The treatment method to the older population and T4 tumor is future tasks.
Authors: Fernando F de Arruda; Dev R Puri; Joanne Zhung; Ashwatha Narayana; Suzanne Wolden; Margie Hunt; Hilda Stambuk; David Pfister; Dennis Kraus; Ashok Shaha; Jatin Shah; Nancy Y Lee Journal: Int J Radiat Oncol Biol Phys Date: 2005-05-31 Impact factor: 7.038
Authors: Elin Ringström; Edward Peters; Masayuki Hasegawa; Marshall Posner; Mei Liu; Karl T Kelsey Journal: Clin Cancer Res Date: 2002-10 Impact factor: 12.531
Authors: Anthony J Cmelak; Sigui Li; Meredith A Goldwasser; Barbara Murphy; Michael Cannon; Harlan Pinto; David I Rosenthal; Maura Gillison; Arlene A Forastiere Journal: J Clin Oncol Date: 2007-09-01 Impact factor: 44.544
Authors: B R Pauloski; J A Logemann; L A Colangelo; A W Rademaker; F M McConnel; M A Heiser; S Cardinale; D Shedd; D Stein; Q Beery; E Myers; J Lewin; M Haxer; R Esclamado Journal: Laryngoscope Date: 1998-06 Impact factor: 3.325
Authors: Kim Huang; Ping Xia; Cynthia Chuang; Vivian Weinberg; Christine M Glastonbury; David W Eisele; Nancy Y Lee; Sue S Yom; Theodore L Phillips; Jeanne M Quivey Journal: Cancer Date: 2008-08-01 Impact factor: 6.860
Authors: D A Fein; W R Lee; W R Amos; R W Hinerman; J T Parsons; W M Mendenhall; S P Stringer; N J Cassisi; R R Million Journal: Int J Radiat Oncol Biol Phys Date: 1996-01-15 Impact factor: 7.038
Authors: Nosayaba Osazuwa-Peters; Sean T Massa; Kara M Christopher; Ronald J Walker; Mark A Varvares Journal: J Cancer Res Clin Oncol Date: 2015-10-28 Impact factor: 4.553
Authors: Anne Marijn Kreeft; Coen R N Rasch; Sara H Muller; Frank A Pameijer; Eeke Hallo; Alfons J M Balm Journal: Eur Arch Otorhinolaryngol Date: 2012-01-05 Impact factor: 2.503